drugset / Trial / NCT01474941
A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects
RandomizedParallel-groupDouble-blind
Summary
The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of PF-04620110 as a modified-release formulation.
Timeline
- Start
- 2011-06
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04620110 | Small molecule | 5 mg | Oral |
Indications
No indication recorded.